deltatrials
Unknown PHASE2 INTERVENTIONAL 4-arm NCT01569516

Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease

A Phase II, Double Blind, Placebo-controlled, Randomized, Multi-Center, Parallel Group Dose Exploring Study to Evaluate the Efficacy and Safety of Octohydroaminoacridine Succinate Tablets in Patient With Mild to Moderate Alzheimer's Disease

Sponsor: Beijing Bionovo Medicine Development Co., Ltd.

Conditions Alzheimer's Disease
Interventions Octohydroaminoacridine Succinate Tablets Octohydroaminoacridine succinate Tablets Placebo
Updated 5 times since 2017 Last updated: Apr 6, 2012 Started: Jun 30, 2011 Primary completion: Jul 31, 2012 Completion: Oct 31, 2012
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Alzheimer's Disease and is currently ongoing. Beijing Bionovo Medicine Development Co., Ltd. leads this study, which shows 5 recorded versions since 2011 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotUnknown Status~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotUnknown Status~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotUnknown~Sep 2024 – present · 23 months · monthly snapshotUnknown

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE2

    Status: Unknown Status → Unknown

  3. Jan 2021 — Jul 2024 [monthly]

    Unknown Status PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Unknown Status PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Unknown Status PHASE2

    First recorded

Jun 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Beijing Bionovo Medicine Development Co., Ltd.
  • Changchun Huayang High-tech Co., Ltd
Data source: Changchun Huayang High-tech Co., Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations